Prevention and treatment of coronavirus infection
- Authors: Isakov V.1,2
-
Affiliations:
- Pavlov First Saint Petersburg State Medical University
- Health Centre for Herpesvirus Infections and Immune Rehabilitation, part of Sokolov Clinical Hospital No. 122
- Issue: Vol 31, No 2 (2020)
- Pages: 72-74
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114179
- DOI: https://doi.org/10.29296/25877305-2020-02-15
- ID: 114179
Cite item
Open Access
Access granted
Abstract
Influenza and other respiratory viruses cause imbalance in the interferon system, and suppression of cellular and phagocytic reactions in vivo. Prolonged persistence of viral and bacterial pathogens affects the atopy development and can lead to exacerbations of chronic respiratory tract diseases. Today the world is concerned with the ongoing epidemic in China caused by a novel RNA virus COVID-2019 (COrona VIrus Disease 2019). This paper presents information about the origin, spread and clinical symptoms of coronavirus infection. Prevention and treatment options for various coronavirus diseases, that can also be helpful in case of C0VID-2019, are discussed.
Keywords
Full Text
About the authors
V. Isakov
Pavlov First Saint Petersburg State Medical University; Health Centre for Herpesvirus Infections and Immune Rehabilitation, part of Sokolov Clinical Hospital No. 122
Email: issakov1945@yandex.ru
References
- Краснов В.В. Эффективность рекомбинантного интерферона-альфа в лечении и профилактике ОРВИ // Вопр. практ. педиатр. - 2016; 11 (4): 44-52 doi: 10.20953/1817-7646-2016-4-44-5
- Дерябин П.Г., Зарубаева В.В. К вопросу о коронавирусной инфекции и перспективах профилактики и лечения препаратами интерферона альфа-2Ь человеческого рекомбинантного // Инфекционные болезни. - 2014; 3: 32-4
- Исследование по оценке противовирусной активности препарата Гриппферон® в отношении коронавирусов, вызывающих Тяжелый Острый Респираторный синдром (SARS) и Ближневосточный респираторный синдром (MERS) URL: https://www.firnm.ru/2020/01/3536-grippferon-assessment-of-antiviral-activity-against-sars-and-mers-coronaviruses/
- Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) // Biosci. Trends. - 2020 Jan 28. doi: 10.5582/bst.2020.01020
- Sheahan T., Sims A., Leist S. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV // Nat. Commun. - 2020; 11 (1): 222. doi: 10.1038/s41467-019-13940-6
Supplementary files
